. .

 
Zuruecksetzen

Suchergebnis - Regeneron Pharmaceuticals

Zeit Titel
25.03 12:46dpa-AFX: Regeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular Lyphoma
25.03 12:13dpa-AFX: *REGENERON: FDA ISSUES CRLS FOR ODRONEXTAMAB BLA IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA AND R/R DIFFUSE LARGE B-CELL LYMPHOMA
11.03 12:33dpa-AFX: Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8
11.03 12:15dpa-AFX: *REGENERON PHARMA: FDA APPROVES PRALUENT INJECTION TO TREAT CHILDREN WITH GENETIC FORM OF HIGH CHOLESTEROL
23.02 07:36dpa-AFX: Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation
21.02 13:50dpa-AFX: Regeneron: Linvoseltamab BLA To Treat RR/MM Accepted For FDA Priority Review
21.02 13:12dpa-AFX: *REGENERON PHARMA: FDA ACCEPTS FOR PRIORITY REVIEW BLA FOR LINVOSELTAMAB FOR TREATMENT OF R/R MULTIPLE MYELOMA
16.02 07:36dpa-AFX: Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment
06.02 12:33dpa-AFX: *DZ BANK RAISES FW FÜR REGENERON PHARMACEUTICALS TO 1068 (915) USD - 'BUY'
06.02 12:33dpa-AFX: *DZ BANK HEBT FW FÜR REGENERON PHARMACEUTICALS AUF 1068 (915) USD - 'KAUFEN'
02.02 13:00dpa-AFX: ROUNDUP: Regeneron Pharma Q4 Results Top Estimates
02.02 12:44dpa-AFX: Regeneron Pharmaceuticals Q4 Profit Decreases, but beats estimates
02.02 12:43dpa-AFX: *REGENERON Q4 NON-GAAP NET INCOME $1.366 BLN VS $1.449 BLN LAST YEAR
02.02 12:41dpa-AFX: *REGENERON Q4 TOTAL REVENUES $3.434 BLN VS $3.414 BLN LAST YEAR
02.02 12:39dpa-AFX: *REGENERON Q4 REVENUES UP 1% TO $3.43 BLN
02.02 12:38dpa-AFX: Regeneron Pharmaceuticals: EMA To Review Marketing Authorization Application For Linvoseltamab
02.02 12:37dpa-AFX: *REGENERON Q4 GAAP EPS $10.19; NON-GAAP EPS $11.86
02.02 12:22dpa-AFX: *REGENERON PHARMA: EMA ACCEPTS FOR REVIEW MAA FOR LINVOSELTAMAB TO TREAT R/R MULTIPLE MYELOMA
30.01 13:33dpa-AFX: Regeneron Announces Formation Of Regeneron Cell Medicines With Acquisition Of 2seventy Bio
30.01 13:05dpa-AFX: *REGENERON ANNOUNCES FORMATION OF REGENERON CELL MEDICINES WITH ACQUISITION OF 2SEVENTY BIO PLATFORMS

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH